TapewireFind a company

person · Reporting owner

Choi Jung

Disclosed activity across 2 companies

Tapewire entity
38057
SEC CIK
0001650126

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Annexon, Inc.ANNX · Entity 5011DirectorJune 11, 2026June 15, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Annexon, Inc.

Report date June 11, 2026 · Filed June 15, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.70 · Expires 2036-06-11Direct65,000 Reported balance After 2026-06-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-11 · Grant · Acquired 65,000 · Balance 65,000

F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Global Blood Therapeutics, Inc.

Report date October 05, 2022 · Filed October 06, 2022

Section 16 reporting ended · disclosed 2022-10-06. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2022-10-05 transaction · row 1
1 source row

Row 1 · 2022-10-05 · Disposition to issuer · Disposed 226,672 · Balance 0

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.

F2: (Continued from footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.

Common StockSEC Table I · non-derivativeIndirectBy Trust0 Reported balance After 2022-10-05 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 2 · 2022-10-05 · Disposition to issuer · Disposed 25,000 · Balance 0

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.

F2: (Continued from footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2022-10-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2022-10-05 · Disposition to issuer · Disposed 3,125 · Balance 0

F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock.

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2022-10-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2022-10-05 · Disposition to issuer · Disposed 9,060 · Balance 0

F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock.

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2022-10-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2022-10-05 · Disposition to issuer · Disposed 13,814 · Balance 0

F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock.

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2022-10-05 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2022-10-05 · Disposition to issuer · Disposed 15,460 · Balance 0

F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock.

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2022-10-05 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2022-10-05 · Disposition to issuer · Disposed 26,454 · Balance 0

F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock.

F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 8,786 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2022-10-05 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2022-10-05 · Disposition to issuer · Disposed 42,400 · Balance 0

F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock.

F6: Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.40Direct0 Reported balance After 2022-10-05 transaction · row 9 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 9 · 2022-10-05 · Disposition to issuer · Disposed 1 · Balance 0

F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.40Direct0 Reported balance After 2022-10-05 transaction · row 10 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 10 · 2022-10-05 · Disposition to issuer · Disposed 1 · Balance 0

F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.40Direct0 Reported balance After 2022-10-05 transaction · row 11 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 11 · 2022-10-05 · Disposition to issuer · Disposed 32,098 · Balance 0

F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.60Direct0 Reported balance After 2022-10-05 transaction · row 12 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 12 · 2022-10-05 · Disposition to issuer · Disposed 35,000 · Balance 0

F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.44Direct0 Reported balance After 2022-10-05 transaction · row 13 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 13 · 2022-10-05 · Disposition to issuer · Disposed 40,000 · Balance 0

F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $65.82Direct0 Reported balance After 2022-10-05 transaction · row 14 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 14 · 2022-10-05 · Disposition to issuer · Disposed 36,225 · Balance 0

F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.48Direct0 Reported balance After 2022-10-05 transaction · row 15 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 15 · 2022-10-05 · Disposition to issuer · Disposed 38,739 · Balance 0

F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.87Direct0 Reported balance After 2022-10-05 transaction · row 16 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 16 · 2022-10-05 · Disposition to issuer · Disposed 28,628 · Balance 0

F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.

F2: (Continued from footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.

F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock.

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.

F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 8,786 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence.

F6: Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time.

F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 11, 2026 Filed Jun 15, 2026 20:15 UTC Annexon, Inc. ANNX · Entity 5011 GrantStock Option (Right to Buy) · Derivative 65,000 $0.00 Strike: $4.70 $0.00
Disclosure

SEC source: 0001650126-26-000001 · form4-06152026_040605.xml · derivative · entry 1

Choi Jung · CIK 0001650126 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2036-06-11

F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date.

Read SEC document
December 01, 2025 Filed Dec 3, 2025 21:30 UTC Annexon, Inc. ANNX · Entity 5011 PurchaseCommon Stock 33,000 $4.19 $138,270.00
Disclosure

SEC source: 0001650126-25-000005 · form4-12032025_041212.xml · nonDerivative · entry 1

Choi Jung · CIK 0001650126 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 33,000

F1 · price: This transaction was executed in multiple trades in prices ranging from $4.165 to $4.215, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote.

F2 · ownership.nature: These shares are held by The Park Family Revocable Trust. The Reporting Person and her spouse are co-trustees of the trust.

Read SEC document
June 05, 2025 Filed Jun 9, 2025 20:20 UTC Annexon, Inc. ANNX · Entity 5011 GrantStock Option (Right to Buy) · Derivative 55,000 $0.00 Strike: $2.55 $0.00
Disclosure

SEC source: 0001415889-25-016245 · form4-06092025_080652.xml · derivative · entry 1

Choi Jung · CIK 0001650126 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2035-06-05

F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 5, 2025 or (ii) the next Annual Meeting following June 5, 2025, subject to Reporting Person's continuous service as a director until such vesting date.

Read SEC document
June 05, 2024 Filed Jun 8, 2024 01:43 UTC Annexon, Inc. ANNX · Entity 5011 GrantStock Option (Right to Buy) · Derivative 44,000 $0.00 Strike: $6.79 $0.00
Disclosure

SEC source: 0001415889-24-016105 · form4-06082024_010637.xml · derivative · entry 1

Choi Jung · CIK 0001650126 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,000

Underlying: Common Stock · 44,000 shares

Expires 2034-06-05

F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 5, 2024 or (ii) the next Annual Meeting following June 5, 2024, subject to Reporting Person's continuous service as a director until such vesting date.

Read SEC document
June 08, 2023 Filed Jun 12, 2023 20:49 UTC Annexon, Inc. ANNX · Entity 5011 GrantStock Option (Right to Buy) · Derivative 24,000 $0.00 Strike: $2.88 $0.00
Disclosure

SEC source: 0001610717-23-000143 · form4.xml · derivative · entry 1

Choi Jung · CIK 0001650126 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires 2033-06-08

F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 8, 2023 or (ii) the next Annual Meeting following June 8, 2023, subject to Reporting Person's continuous service as a director until such vesting date.

Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:15 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Disposition to issuerStock Option (Right to Buy) · Derivative 28,628 Not disclosed Strike: $29.87 Not disclosed
Disclosure

SEC source: 0000899243-22-033148 · doc4.xml · derivative · entry 16

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 28,628 shares

Expires not disclosed

F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:15 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Disposition to issuerStock Option (Right to Buy) · Derivative 38,739 Not disclosed Strike: $44.48 Not disclosed
Disclosure

SEC source: 0000899243-22-033148 · doc4.xml · derivative · entry 15

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 38,739 shares

Expires not disclosed

F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:15 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Disposition to issuerStock Option (Right to Buy) · Derivative 36,225 Not disclosed Strike: $65.82 Not disclosed
Disclosure

SEC source: 0000899243-22-033148 · doc4.xml · derivative · entry 14

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 36,225 shares

Expires not disclosed

F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:15 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Disposition to issuerStock Option (Right to Buy) · Derivative 40,000 Not disclosed Strike: $48.44 Not disclosed
Disclosure

SEC source: 0000899243-22-033148 · doc4.xml · derivative · entry 13

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires not disclosed

F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:15 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Disposition to issuerStock Option (Right to Buy) · Derivative 35,000 Not disclosed Strike: $59.60 Not disclosed
Disclosure

SEC source: 0000899243-22-033148 · doc4.xml · derivative · entry 12

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 35,000 shares

Expires not disclosed

F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:15 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Disposition to issuerStock Option (Right to Buy) · Derivative 32,098 Not disclosed Strike: $16.40 Not disclosed
Disclosure

SEC source: 0000899243-22-033148 · doc4.xml · derivative · entry 11

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 32,098 shares

Expires not disclosed

F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:15 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Disposition to issuerStock Option (Right to Buy) · Derivative 1 Not disclosed Strike: $3.40 Not disclosed
Disclosure

SEC source: 0000899243-22-033148 · doc4.xml · derivative · entry 10

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1 shares

Expires not disclosed

F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:15 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Disposition to issuerStock Option (Right to Buy) · Derivative 1 Not disclosed Strike: $3.40 Not disclosed
Disclosure

SEC source: 0000899243-22-033148 · doc4.xml · derivative · entry 9

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1 shares

Expires not disclosed

F7 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:15 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Disposition to issuerRestricted Stock Units · Derivative 42,400 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-033148 · doc4.xml · derivative · entry 8

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 42,400 shares

Expires not disclosed

F3 · derivative.exercise_price: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock.

F6 · price: Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time.

F6 · derivative.exercise_date: Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time.

F6 · derivative.expiration_date: Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time.

Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:15 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Disposition to issuerRestricted Stock Units · Derivative 26,454 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-033148 · doc4.xml · derivative · entry 7

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 26,454 shares

Expires not disclosed

F3 · derivative.exercise_price: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock.

F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 8,786 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence.

F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 8,786 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence.

F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 8,786 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence.

Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:15 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Disposition to issuerRestricted Stock Units · Derivative 15,460 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-033148 · doc4.xml · derivative · entry 6

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,460 shares

Expires not disclosed

F3 · derivative.exercise_price: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock.

F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.

Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:15 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Disposition to issuerRestricted Stock Units · Derivative 13,814 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-033148 · doc4.xml · derivative · entry 5

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,814 shares

Expires not disclosed

F3 · derivative.exercise_price: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock.

F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.

Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:15 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Disposition to issuerRestricted Stock Units · Derivative 9,060 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-033148 · doc4.xml · derivative · entry 4

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,060 shares

Expires not disclosed

F3 · derivative.exercise_price: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock.

F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.

Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:15 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Disposition to issuerRestricted Stock Units · Derivative 3,125 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-033148 · doc4.xml · derivative · entry 3

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,125 shares

Expires not disclosed

F3 · derivative.exercise_price: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock.

F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.

Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:15 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Disposition to issuerCommon Stock 25,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-033148 · doc4.xml · nonDerivative · entry 2

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 0

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.

F2 · price: (Continued from footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.

Read SEC document
October 05, 2022 Filed Oct 6, 2022 16:15 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Disposition to issuerCommon Stock 226,672 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-033148 · doc4.xml · nonDerivative · entry 1

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.

F2 · price: (Continued from footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.

Read SEC document
September 29, 2022 Filed Sep 29, 2022 20:43 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 GiftCommon Stock 73,855 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-032260 · doc4.xml · nonDerivative · entry 6

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 226,672

Read SEC document
September 27, 2022 Filed Sep 29, 2022 20:43 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Exercise / conversionStock Option (Right to Buy) · Derivative 2,674 $0.00 Strike: $3.40 $0.00
Disclosure

SEC source: 0000899243-22-032260 · doc4.xml · derivative · entry 12

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1

Underlying: Common Stock · 2,674 shares

Expires 2025-04-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On September 29, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option.

Read SEC document
September 27, 2022 Filed Sep 29, 2022 20:43 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Exercise / conversionStock Option (Right to Buy) · Derivative 2,674 $0.00 Strike: $3.40 $0.00
Disclosure

SEC source: 0000899243-22-032260 · doc4.xml · derivative · entry 11

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1

Underlying: Common Stock · 2,674 shares

Expires 2025-04-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On March 10, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option.

Read SEC document
September 27, 2022 Filed Sep 29, 2022 20:43 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Exercise / conversionStock Option (Right to Buy) · Derivative 74,964 $0.00 Strike: $3.40 $0.00
Disclosure

SEC source: 0000899243-22-032260 · doc4.xml · derivative · entry 10

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 74,964 shares

Expires 2025-04-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The shares of Common Stock underlying the stock option vested as to 25% of the original grant for 77,142 shares on April 6, 2016 and in 12 equal quarterly installments thereafter through April 6, 2019.

Read SEC document
September 27, 2022 Filed Sep 29, 2022 20:43 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Exercise / conversionStock Option (Right to Buy) · Derivative 2,275 $0.00 Strike: $65.82 $0.00
Disclosure

SEC source: 0000899243-22-032260 · doc4.xml · derivative · entry 9

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,225

Underlying: Common Stock · 2,275 shares

Expires 2030-02-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares of Common Stock underlying the option vest in 16 equal quarterly installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

Read SEC document
September 27, 2022 Filed Sep 29, 2022 20:43 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Exercise / conversionStock Option (Right to Buy) · Derivative 16,902 $0.00 Strike: $16.40 $0.00
Disclosure

SEC source: 0000899243-22-032260 · doc4.xml · derivative · entry 8

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,098

Underlying: Common Stock · 16,902 shares

Expires 2027-01-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares of Common Stock underlying the option vested in equal quarterly installments over 16 quarters from January 17, 2017 through January 17, 2021.

Read SEC document
September 27, 2022 Filed Sep 29, 2022 20:43 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Exercise / conversionCommon Stock 2,674 $3.40 $9,091.60
Disclosure

SEC source: 0000899243-22-032260 · doc4.xml · nonDerivative · entry 5

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,527

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 27, 2022 Filed Sep 29, 2022 20:43 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Exercise / conversionCommon Stock 2,674 $3.40 $9,091.60
Disclosure

SEC source: 0000899243-22-032260 · doc4.xml · nonDerivative · entry 4

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 297,853

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 27, 2022 Filed Sep 29, 2022 20:43 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Exercise / conversionCommon Stock 74,964 $3.40 $254,877.60
Disclosure

SEC source: 0000899243-22-032260 · doc4.xml · nonDerivative · entry 3

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 295,179

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 27, 2022 Filed Sep 29, 2022 20:43 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Exercise / conversionCommon Stock 2,275 $65.82 $149,740.50
Disclosure

SEC source: 0000899243-22-032260 · doc4.xml · nonDerivative · entry 2

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 220,215

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 27, 2022 Filed Sep 29, 2022 20:43 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Exercise / conversionCommon Stock 16,902 $16.40 $277,192.80
Disclosure

SEC source: 0000899243-22-032260 · doc4.xml · nonDerivative · entry 1

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 217,940

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 01, 2022 Filed Sep 6, 2022 19:00 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Exercise / conversionRestricted Stock Units · Derivative 2,208 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-030474 · doc4.xml · derivative · entry 6

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,460

Underlying: Common Stock · 2,208 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

F4 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

Read SEC document
September 01, 2022 Filed Sep 6, 2022 19:00 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Exercise / conversionRestricted Stock Units · Derivative 2,763 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-030474 · doc4.xml · derivative · entry 5

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,814

Underlying: Common Stock · 2,763 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F3 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

F3 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

Read SEC document
September 01, 2022 Filed Sep 6, 2022 19:00 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Tax withholdingCommon Stock 1,861 $68.15 $126,827.15
Disclosure

SEC source: 0000899243-22-030474 · doc4.xml · nonDerivative · entry 3

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 201,038

F2 · shares: Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 4,971 shares of Common Stock underlying the Reporting Person's RSUs.

Read SEC document
September 01, 2022 Filed Sep 6, 2022 19:00 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Exercise / conversionCommon Stock 2,208 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-030474 · doc4.xml · nonDerivative · entry 2

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 202,899

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

Read SEC document
September 01, 2022 Filed Sep 6, 2022 19:00 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Exercise / conversionCommon Stock 2,763 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-030474 · doc4.xml · nonDerivative · entry 1

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,691

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

Read SEC document
August 01, 2022 Filed Aug 3, 2022 18:01 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Exercise / conversionRestricted Stock Units · Derivative 3,020 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-027636 · doc4.xml · derivative · entry 5

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,060

Underlying: Common Stock · 3,020 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F5 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

F5 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

Read SEC document
August 01, 2022 Filed Aug 3, 2022 18:01 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Exercise / conversionRestricted Stock Units · Derivative 3,125 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-027636 · doc4.xml · derivative · entry 4

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,125

Underlying: Common Stock · 3,125 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

F4 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

Read SEC document
August 01, 2022 Filed Aug 3, 2022 18:01 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Tax withholdingCommon Stock 2,126 $32.40 $68,882.40
Disclosure

SEC source: 0000899243-22-027636 · doc4.xml · nonDerivative · entry 2

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 197,928

F3 · shares: Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 6,145 shares of Common Stock underlying the Reporting Person's RSUs.

Read SEC document
August 01, 2022 Filed Aug 3, 2022 18:01 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Exercise / conversionCommon Stock 6,145 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-027636 · doc4.xml · nonDerivative · entry 1

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,054

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · balance_after: The number of shares of the Issuer's Common Stock beneficially owned by the Reporting Person includes 2,535 shares, which, as a result of an administrative error by no fault of the Reporting Person, were inadvertently omitted from the Table I, Column 5 share totals disclosed on Forms 4 filed on behalf of the Reporting Person from August 31, 2017 to the present.

Read SEC document
June 09, 2022 Filed Jun 13, 2022 20:34 UTC Annexon, Inc. ANNX · Entity 5011 GrantStock Option (Right to Buy) · Derivative 24,000 $0.00 Strike: $3.84 $0.00
Disclosure

SEC source: 0001567619-22-012775 · doc1.xml · derivative · entry 1

Choi Jung · CIK 0001650126 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires 2032-06-09

F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 9, 2022 or (ii) the next Annual Meeting following June 9, 2022, subject to Reporting Person's continuous service as a director until such vesting date.

Read SEC document
March 01, 2022 Filed Mar 3, 2022 21:07 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 GrantStock Option (Right to buy) · Derivative 28,628 $0.00 Strike: $29.87 $0.00
Disclosure

SEC source: 0000899243-22-009253 · doc4.xml · derivative · entry 7

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,628

Underlying: Common Stock · 28,628 shares

Expires 2032-02-28

F6 · derivative.exercise_date: The shares of Common Stock underlying the stock option vest in 16 equal quarterly installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

Read SEC document
March 01, 2022 Filed Mar 3, 2022 21:07 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 GrantRestricted Stock Units · Derivative 17,668 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-009253 · doc4.xml · derivative · entry 6

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,668

Underlying: Common Stock · 17,668 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F5 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in two installments, if at all, based on (i) the Issuer's total shareholder return percentile ranking relative to the companies in the NASDAQ Biotechnology Index for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date, and (ii) the percentage of patient share relative to a comparator group for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

F5 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in two installments, if at all, based on (i) the Issuer's total shareholder return percentile ranking relative to the companies in the NASDAQ Biotechnology Index for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date, and (ii) the percentage of patient share relative to a comparator group for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

Read SEC document
March 01, 2022 Filed Mar 3, 2022 21:07 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 GrantRestricted Stock Units · Derivative 17,668 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-009253 · doc4.xml · derivative · entry 5

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,668

Underlying: Common Stock · 17,668 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

F4 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

Read SEC document
March 01, 2022 Filed Mar 3, 2022 21:07 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Exercise / conversionRestricted Stock Units · Derivative 2,763 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-009253 · doc4.xml · derivative · entry 4

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,577

Underlying: Common Stock · 2,763 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F3 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

F3 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

Read SEC document
March 01, 2022 Filed Mar 3, 2022 21:07 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Tax withholdingCommon Stock 956 $29.87 $28,555.72
Disclosure

SEC source: 0000899243-22-009253 · doc4.xml · nonDerivative · entry 2

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 191,374

F2 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 2,763 shares of Common Stock underlying the Reporting Person's RSUs.

Read SEC document
March 01, 2022 Filed Mar 3, 2022 21:07 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Exercise / conversionCommon Stock 2,763 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-22-009253 · doc4.xml · nonDerivative · entry 1

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 192,330

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

Read SEC document
February 01, 2022 Filed Feb 3, 2022 17:43 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Exercise / conversionRestricted Stock Units · Derivative 3,020 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-004633 · doc4.xml · derivative · entry 6

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,080

Underlying: Common Stock · 3,020 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F5 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

F5 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

Read SEC document
February 01, 2022 Filed Feb 3, 2022 17:43 UTC Global Blood Therapeutics, Inc. GBT · Entity 123220 Exercise / conversionRestricted Stock Units · Derivative 3,125 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-004633 · doc4.xml · derivative · entry 5

Choi Jung · CIK 0001650126 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,250

Underlying: Common Stock · 3,125 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

F4 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.